Pharmacological targeting of adenosine receptor signaling

被引:57
|
作者
Peleli, Maria [1 ]
Fredholm, Bertil B. [1 ]
Sobrevia, Luis [2 ,3 ,4 ]
Carlstrom, Mattias [1 ]
机构
[1] Karolinska Inst, Dept Physiol & Pharmacol, Nanna Svartz Vag 2, SE-17177 Stockholm, Sweden
[2] Pontificia Univ Catolica Chile, Div Obstet & Gynaecol, CMPL, Sch Med,Fac Med, Santiago 8330024, Chile
[3] Univ Seville, Dept Physiol, Fac Pharm, E-41012 Seville, Spain
[4] Univ Queensland, Fac Med & Biomed Sci, UQCCR, Herston, Qld 4029, Australia
基金
瑞典研究理事会;
关键词
Adenosine; Adenosine receptor; Drug target; Drug discovery; Pharmacology; Disease; UMBILICAL VEIN ENDOTHELIUM; L-ARGININE TRANSPORT; INTERNATIONAL UNION; PARKINSONS-DISEASE; INSULIN-RESISTANCE; OXIDATIVE STRESS; CAFFEINE THERAPY; MICE; BRAIN; ANTAGONIST;
D O I
10.1016/j.mam.2016.12.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Adenosine receptor signaling plays important roles in normal physiology, but is also known to modulate the development or progression of several different diseases. The design of new, efficient, and safe pharmacological approaches to target the adenosine system may have considerable therapeutic potential, but is also associated with many challenges. This review summarizes the main challenges of adenosine receptor targeted treatment including tolerance, disease stage, cell type-specific effects, caffeine intake, adenosine level assessment and receptor distribution in vivo. Moreover, we discuss several potential ways to overcome these obstacles (i.e., the use of partial agonists, indirect receptor targeting, allosteric enhancers, prodrugs, non-receptor-mediated effects, neoreceptors, conditional knockouts). It is important to address these concerns during development of new and successful therapeutic approaches targeting the adenosine system. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4 / 8
页数:5
相关论文
共 50 条
  • [21] Yeast as a platform to study adenosine receptor signaling
    Jain, Abhinav
    Robinson, Anne
    McGraw, Claire
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 255
  • [22] Mast cell adenosine receptor characteristics and signaling
    Marquardt, DL
    PURINE AND PYRIMIDINE METABOLISM IN MAN IX, 1998, 431 : 79 - 82
  • [23] Adenosine receptor signaling and coronary flow regulation
    Mustafa, S. Jamal
    PURINERGIC SIGNALLING, 2010, 6 : 28 - 29
  • [24] Targeting Adenosine Receptors: A Potential Pharmacological Avenue for Acute and Chronic Pain
    Vincenzi, Fabrizio
    Pasquini, Silvia
    Borea, Pier Andrea
    Varani, Katia
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (22) : 1 - 21
  • [25] Multiple Ways of Targeting the Adenosine/Adenosine Receptor Axis in Lung Inflammation and Injury
    Majetschak, Matthias
    CRITICAL CARE MEDICINE, 2016, 44 (04) : 853 - 854
  • [26] Pharmacological characterisation of novel adenosine A3 receptor antagonists
    Barkan, Kerry
    Lagarias, Panagiotis
    Stampelou, Margarita
    Stamatis, Dimitrios
    Hoare, Sam
    Safitri, Dewi
    Klotz, Karl-Norbert
    Vrontaki, Eleni
    Kolocouris, Antonios
    Ladds, Graham
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [27] Pharmacological and therapeutic effects of A3 adenosine receptor agonists
    Fishman, Pnina
    Bar-Yehuda, Sara
    Liang, Bruce T.
    Jacobson, Kenneth A.
    DRUG DISCOVERY TODAY, 2012, 17 (7-8) : 359 - 366
  • [28] Pharmacological characterisation of novel adenosine A3 receptor antagonists
    Kerry Barkan
    Panagiotis Lagarias
    Margarita Stampelou
    Dimitrios Stamatis
    Sam Hoare
    Dewi Safitri
    Karl-Norbert Klotz
    Eleni Vrontaki
    Antonios Kolocouris
    Graham Ladds
    Scientific Reports, 10
  • [29] Cloning and pharmacological characterization of the equine adenosine A3 receptor
    Brandon, C. I.
    Vandenplas, M.
    Dookwah, H.
    Murray, T. F.
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2006, 29 (04) : 255 - 263
  • [30] Investigational A3 adenosine receptor targeting agents
    Koscso, Balazs
    Csoka, Balazs
    Pacher, Pal
    Hasko, Gyoergy
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (06) : 757 - 768